Perinatal transmission of HIV

Current Opinion in Infectious Diseases

Volumn 10, Issue 3, 1997, Pages 239-245

  Hermione Lyall, E G ^a,b   Tudor Williams, Gareth ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RETINOL;

DELIVERY; DIET SUPPLEMENTATION; EARLY DIAGNOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NEWBORN; PERINATAL PERIOD; PLACENTA; PREGNANCY; REVIEW; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 0030990048     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199706000-00014     Document Type: Review

References (56)

1. Bryson YJ, Luzuriaga K, Sullivan JL, Wara D: Proposed definitions for in-utero versus intrapartum transmission of HIV-1. N Engl J Med 1992, 327:1246-1247.
2. Kuhn L, Abrams E, Matheson P, Thomas P, Lambert G, Bamji M, Greenberg B, Steketee R, Thea D and New York City Perinatal Transmission Collaborative Study Group: Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. AIDS 1997, 11:429-435. A prospective study of 276 mother-infant pairs in whom early infant PCR results (4 hours) and prematurity (<37 weeks gestation) were associated with significantly higher transmission rates for vaginally delivered infants with presumed intrapartum infection, but not for those with presumed intrauterine infection.
3. Sperling RS, Shapiro DS, Coombs RW, Todd JA, Herman SA, McSherry GD, O'Sullivan MJ, Van Dyke RB, Jimenez E, Rouzioux C et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of HIV-1 from mother to infant. N Engl J Med 1996, 335:1621-1629. A further analysis of the ACTG 076 study including viral load data, indicating that the protective effect of AZT treatment occurs not solely because of a reduction in maternal virus load, but may also be acting as pre-exposure prophylaxis for the fetus and infant.
4. The Working Group on Mother-to-Child Transmission of HIV: Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr and Hum Retrovirol 1995, 8:506-510.
5. Simonds RJ, Nesheim S, Matheson P, Abrams E, Vink P, Palumbo R, Steketee: Declining mother-to-child HIV transmission following perinatal zidovudine recommendations, United States Xlth International Conference on AIDS, Vancouver, 1996, (Abstract Tu.C.440).
6. Davis SF, Byers RH, Lindgren ML, Caldwell MB, Karon JM, Gwinn M: Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 1995, 274:952-955.
7. Ecker JL: The cost-effectiveness of HIV screening in pregnancy. Am J Obstet Gynecol 1996, 174:716-721. A mathematical model based on US healthcare costs, suggesting that testing in pregnancy becomes cost-effective in populations with a prevalence of over 9 per 1000.
8. Tovo P-A, de Martino M, Gabiano C, Galli L, Cappello N, Ruga E, Tulisso S, Vierucci A, Loy A, Zuccotti GV et al.: Mode of delivery and gestational age influence perinatal HIV-1 transmission. J Acquir Immune Defic Syndr and Hum Retrovirol 1996, 11:88-94. A multivariate analysis of data from the Italian Register for HIV infection in Children on 1033 infants. Vaginal delivery and prematurity (<32 weeks) were associated with a higher risk of transmission.
9. Mayaux M-J, Blanche S, Rouzioux C, Le Chenadec J, Chambrin V, Firtion G, Allemon MC, Vimer E, Vilmer E, Vigneron NC, Tricoire J et al. Maternal factors associated with perinatal HIV-1 transmission: the French Cohort Study: 7 years of follow-up observation. J Acquir Immune Defic Syndr and Hum Retrovirol 1995, 8:188-194.
10. Fang G, Burger H, Grimson R, Tropper P, Nachman S, Mayers D, Weilsow O, Moore R, Reyelt C, Hutcheon N, Baker D, Weiser B: Maternal plasma HIV-1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci U S A 1995, 92:12100-12104.
11. Dickover RE, Garratty EM, Herman SA, Sim M-S, Plaeger S, Boyer PJ, Keller M, Deveikis A, Stiehm R, Bryson YJ: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. JAMA 1996, 275:599-605. A study of 97 infants born to 92 mothers, demonstrating that mothers with over 50 000 copies per ml were more likely to transmit.
12. Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorrilla C, Garcia P, Fowler MG, Mofenson L, Tuomala R: Obstetric factors and the transmission of HIV-1 from mother to child. N Engl J Med 1996, 334:1617-1623. A multivariate analysis of data from the WITS on 525 mother-infant pairs. Presence of ruptured membranes for over 4 h nearly doubled the risk of transmission, regardless of the mode of delivery.
13. ••], on 535 pregnancies; 42% of mothers used hard drugs in pregnancy(!).
14. Bloland PB, Wirima JJ, Steketee RW, Chilima B, Hightower A, Breman JG: Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. AIDS 1995, 9:721-726.
15. Semba RD, Miotti PG, Chiphangwi JD, Liomba G, Yang LP, Saah AJ, Dallabetta GA, Hoover DR: Infant mortality and vitamin A deficiency during human immunodeficiency virus infection. Clin Infect Dis 1995, 21:966-972.
16. Nduati RW, John GC, Richardson BA, Overbaugh J, Welch M, Ndinyaachola J, Moses S, Holmes K, Onyango F, Kreiss JK: HIV-1 infected cells in breast milk: association with immunosuppression and vitamin A deficiency. J Infect Dis 1995, 172:1461-1468.
17. Landesman SH, Burns D: Quantifying HIV. JAMA 1996, 275:640-641.
18. Brossard Y, Aubin J-T, Mandelbrot L, Bignozzi C, Brand D, Chaput A, Roumes J, Mulliez N, Mallet F, Agut H et al.: Frequency of early inutero HIV-1 infection: a blind study of DNA polymerase chain reaction study on 100 fetal thymuses. AIDS 1995, 9:359-366.
19. Langston C, Lewis DE, Hammill HA, Popek EJ, Kozinetz CA, Kline MW, Hanson IC, Shearer WT: Excess intrauterine fetal demise associated with maternal immunodeficiency virus infection. J Infect Dis 1995, 172:1451-1460.
20. Kourtis AP, Ibegbu C, Nahmias AJ, Lee FK, Clark WS, Sawyer MK, Nesheim S: Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med 1996, 335:1431-1436.
21. Rasheed S, Li Z, Xu D, Kovacs A: Presence of cell-free HIV in the cervical secretions is independent of viral load in the blood of HIV-infected women. Am J Obstet Gynecol 1996, 175:122-130. A detailed virological study of 63 non-pregnant women, showing no correlation between virus load in the circulation and the presence or absence of quantifiable HIV in the CVSs.
22. Henin Y, Mandelbrot L, Henrion R, Pradinaud R, Coulaud J, Mantagnier I: Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Imm Defic Syndromes 1993, 6:72-75.
23. Clemetson D, Moss G, Willerford D, Hensel M, Emonyi W, Holmes K, Plummer F, Ndinya-Achola J, Roberts P, Hillier S et al.: Detection of HIV DNA in cervical and vaginal secretions. JAMA 1993, 269:2860-2864.
24. Nielsen K, Boyer P, Dillon MF, Wafer D, Wei LS, Garratty E, Dickover RE, Bryson YJ: Presence of HIV-1 and HIV-1 specific antibodies in the cervicovaginal secretions of infected mothers and in the gastric aspirates of their infants. J Infect Dis 1996, 173:1001-1004. Seven out of 25 women had detectable HIV in their CVSs. Virus was detectable even in the presence of HIV-specific secretory IgA. Again, a poor correlation with circulating virus load was noted. Two out of four infected infants had culturable HIV in their gastric aspirates at delivery, supporting mucosal exposure as the route of infection.
25. Soto-Ramirez LE, Renjifo B, McLane MF, Marlink R, O'Hara C, Sitthent R, Wasi C, Vithayasai P, Vithayasai V, Apichartpiyakul C et al.: HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 1996, 271:1291-1293. HIV subtype E from Thai heterosexuals grew more efficiently in Langerhans' cells than subtype B isolates from US homosexuals. Preliminary data supports the hypothesis that the E clade viruses may be more efficiently transmitted heterosexually.
26. Matheson PB, Thomas PA, Abrams EJ, Pliner V, Lambert G, Bamji M, Krasinski K, Steketee R, Chiasson MA, Thea DM: Hetero-sexual behaviour during pregnancy and a perinatal transmission of HIV-1. AIDS 1996, 10:1249-1256. A high frequency of unprotected sexual intercourse in pregnancy was associated with a higher risk of transmission in a retrospective analysis of 175 New York City mothers.
27. Baba TW, Koch J, Mittler ES, Greene M, Wyand M, Penninck D, Ruprecht RM: Mucosal infection of neonatal rhesus monkeys with cell free SIV. AIDS Res Hum Retroviruses 1994, 10:351-357.
28. Duliege A-M, Amos CI, Felton S, Biggar RJ, Goedert JJ: Birth order, delivery route, and concordance in the transmission of HIV-1 from mothers to twins. J Pediatr 1995, 126:625-632.
29. Minkoff H, Burns DN, Landesman S, Youchah J, Goedert J, Nugent RP, Muenz LR, Willoughby AD: The relationship of the duration of ruptured membranes to vertical transmission of HIV. Am J Obstet Gynecol 1995, 173:585-589.
30. European Collaborative Study: Caesarean section and risk of vertical transmission of HIV-1 infection. Lancet 1994, 343:1464-1467.
31. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan M, Van Dyke R, Bey M, Shearer W, Jacobsen R et al.: Reduction of maternal-infant transmission of HIV-1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
32. Wiznia AA, Crane M, Lambert G, Sansary J, Harris A, Solomon L: Zidovudine use to reduce perinatal HIV-1 transmission in an urban medical centre. JAMA 1996, 275:1504-1506. A study of the uptake of AZT by pregnant women in the Bronx after the ACTG 076 trial. A total of 75% of mothers who knew their HIV status elected to have AZT but compliance was a problem in association with continued cocaine use in pregnancy.
33. Fiscus SA, Adimora AA, Schoenbach VJ, Lim W, Mckinney R, Rupar D, Kenny J, Woods C, Wilfert C: Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996, 275:1483-1488. A more encouraging report from North Carolina, showing more than 90% uptake of testing, 75% acceptance of AZT intervention, and a reduction in transmission from 18.9% to 5.7%.
34. Blanche S, Mayaux MJ, Mandelbrot L, Rouzioux C et al. Acceptability and impact of zidovudine prevention on mother-to-child HIV-1 transmission in France. 4th International Conference on Retroviruses and Opportunistic Infections. A nationwide prospective cohort study from France highlighting a greater than 90% uptake of testing in pregnancy, 99% acceptance of AZT, and a reduction in transmission to 5% (±2%). This is a challenge to countries such as the UK, where currently less than 20% of HIV-infected mothers are being identified during pregnancy.
35. Frenkel LM, Wagner LE, Demeter LM, Dewhurst S, Coombs RW, Murante BL, Reichman RC: Effects of zidovudine use during pregnancy on resistance and vertical transmission of HIV-1. Clin Ind Dis 1995, 20:1321-1326.
36. Srinivas RV, Holden WT, Su T, Flynn PM: Development of zidovudine-resistant HIV genotypes following postnatal prophylaxis in a perinatally infected infant. AIDS 1996, 7:795-797. A case report of an infant who was infected despite perinatal use of AZT, and at 12 weeks of age harboured virus with multiple resistance mutations to AZT.
37. Siegrist CA, Yerly S, Kaiser L, Wyler CA, Perrin L: Mother-to-child transmission of zidovudine-resistant HIV-1. Lancet 1994, 344: 1771-1772.
38. Biggar RJ, Miotti PG, Taha TE, Mtimavalye L, Broadhead R, Justesen A, Yellin F, Liomba G, Miley W, Waters D et al.: Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996, 347:1647-1650. An ambitious study of almost 7000 mothers in Malawi, which assessed whether cleansing the birth canal during labour with 0.25% chlorhexidine might reduce the transmission of HIV. It did not, except in the subgroup whose membranes were ruptured for over 4 h. Postpartum infections in the mothers were, however, lower, and neonatal sepsis was reduced.
39. Kuhn L, Bobat R, Coutsoudis A, Moodley D, Coovadia HM, Tsai W-Y, Stein ZA: Caesarean deliveries and maternal-infant HIV transmission: results from a prospective study in South Africa. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:478-483. Despite a predominance of breast feeding, infants delivered by Caesarean section were less likely to be infected (22.9%) than those delivered vaginally (39.8%), when assessed at over 15 months of age.
40. Owens DK, Holodniy M, McDonald TW, Scott J, Sonnad S: A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants. JAMA 1996, 275:1342-1348. A meta-analysis of 32 studies of DNA PCR for the diagnosis of HIV infection in infants. Joint sensitivity and specificity was 93% for neonates less than 30 days of age, and 98% for older infants.
41. Luzuriaga K, Sullivan JL: DNA polymerase chain reaction for the diagnosis of vertical HIV infection. JAMA 1996, 275:1360-1361.
42. McMichael A, Koup R, Ammann AJ: Transient HIV infection in infants. N Engl J Med 1996, 334:801-802.
43. Fauci AS: Host factors and the pathogenesis of HIV-induced disease. Nature 1996, 384:529-534. A well balanced and comprehensive review.
44. Haynes BF, Pantaleo G, Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996, 271:324-328. A useful review of the protective immunological responses in long term non-progressors.
45. Hill CM, Littman DR: Natural resistance to HIV? Nature 1996, 382:668-669.
46. Just JJ, Abrams E, Louie LG, Urbano R, Nicholas SW, Stein Z, King MC: Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with HIV-1. J Podiatr 1995, 127:544-549.
47. Halapi E, Gigliotti D, Hodara V, Scarlatti G, Tovo PA, Demaria A, Wigzell H, Rossi P: Detection of CD8 T-cell expansions with restricted T-cell receptor V gene usage in infants vertically infected by HIV-1 AIDS 1996, 10:1621-1626.
48. Abrams EJ, Matheson PB, Thomas PB, Thea DM, Krasinski K, Lambert G, Shaffer N, Bamji M, Hutson D, Grimm K et al.: Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. Pediatrics 1995, 96:451-458.
49. Palumbo PE, Kwok S, Waters S, Wesley Y, Lewis D, McKinney N, Bardeguez A, Connor EM, Oleske JM: Viral measurement by polymerase chain reaction-based assays in HIV-infected infants. J Pediatr 1995, 126:592-595.
50. McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, Karthas N, Burchert SK: Age- and time-related changes in extracellular viral load in children vertically infected by HIV. Pediatr Infect Dis J 1996, 15:10870-10891.
51. Tetali S, Abrams E, Bakshi S, Paul M, Oyaizu N, Pahwa S: Virus load as a marker of disease progression in HIV-infected children. AIDS Res Hum Retroviruses 1996, 12:669-675. A study of 47 HIV infected children, showing that a higher cell-associated virus load in early life was associated with more rapid disease progression.
52. De Rossi A, Masiero S, Giaquinto C, Ruga E, Comar M, Giacca M, Chieco-Bianchi L: Dynamics of viral replication in infants with vertically acquired HIV-1 infection. J Clin Invest 1996, 97:323-330. A detailed study of 11 HIV-infected infants followed prospectively from birth. Data suggests that, as in adults, infants also develop individual 'set-points' for viral load. Those infants with higher viral loads in the first 2-3 months of life had a more rapid disease progression.
53. Barnhart HX, Caldwell MB, Thomas P, Mascola L, Ortiz I, Hsu H-W, Schulte J, Parrott R, Maldonaldo Y, Byers R: Natural history of HIV disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996, 97:710-716. An analysis of data on 2148 perinatally infected children. Markov modelling was used to describe the 'natural history'. Sixty-nine per cent had some signs or symptoms by 1 year, but 72% were surviving longer than 4 years. This analysis did not take into account the wide variations in approaches to treatment in the different centres.
54. Mayaux MJ, Burgard M, Teglas JP, Cottalorda J, Krivine A, Simon F, Puel J, Tamalet C, Dormont D, Masquelier B et al. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. JAMA 1996, 275:606-610. A multicentre French study of 1386 perinatally exposed children. Positive PCR or culture or p24 antigenaemia in the first week of life was associated with rapid disease progression.
55. Bush CE, Donovan RM, Manzor O, Baxa D, Moore E, Cohen F, Saravolatz LD: Comparison of HIV-1 RNA plasma viremia, p24 antigenaemia, and unintegrated DNA as viral load markers in pediatric patients. AIDS Res Hum Retroviruses 1996, 12:11-15.
56. MacDonagh SE, Masters J, Helps BA, Tookey PA, Aedes AE, Gibb DM: Descriptive survey of antenatal HIV testing in London: policy, uptake and detection. BMJ 1996, 313:532-533.